Skip to content
ChickenStockChickenStock
ResearchBLTE
Belite Bio logo

Belite Bio (BLTE) stock

NASDAQ

$164.78-3.05%(-5.18)

As of the Nov 13, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Latest fiscal year

Latest fiscal-year financials · Computed in-house by ChickenStock

P/E

-82.38x

Net loss — not comparable

P/B

8.35x

P/S

—

Latest earnings

Recent results in a standard quarterly format were not found in SEC filings.

Some foreign companies file only annual or current reports, so quarterly figures may be missing.

See recent SEC filings →

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • Lin Yu-HsinChief Executive Officer · Oct 29, 2026Other5,000 shares · $0
    Avg. price $0187,949 shares held after
  • Chuang Hao-YuanChief Financial Officer · Oct 29, 2026Other5,000 shares · $0
    Avg. price $0180,264 shares held after
  • Scholl Hendrik PeterChief Medical Officer · Oct 1, 2026Open-market sale500 shares · $83K
    Avg. price $165.3178
    Show 8 price lots
    • 200 shares × $163.625$33K
    • 120 shares × $165.4935$20K
    • 78 shares × $167.5876$13K
    • 50 shares × $166.4368$8K
    • 24 shares × $164.6408$4K
    • 14 shares × $169.36$2K
    • 12 shares × $168.2117$2K
    • 2 shares × $170.02$340
  • Chen Wan-ShanDirector · Sep 24, 2026Option exercise (expiring)13,796 shares · $6K
    Avg. price $0.438637,259 shares held after
  • Lin Yu-HsinChief Executive Officer · Sep 8, 2026Open-market sale26,000 shares · $5.1M
    Avg. price $196.5571
    Show 5 price lots
    • 8,752 shares × $197.3577$1.7M
    • 6,090 shares × $195.6199$1.2M
    • 6,058 shares × $196.5405$1.2M
    • 2,700 shares × $198.0907$535K
    • 2,400 shares × $194.3328$466K
  • Chuang Hao-YuanChief Financial Officer · Sep 8, 2026Open-market sale17,962 shares · $3.5M
    Avg. price $196.4224
    Show 5 price lots
    • 4,605 shares × $197.2299$908K
    • 4,475 shares × $196.4692$879K
    • 4,120 shares × $195.6041$806K
    • 2,562 shares × $198.0454$507K
    • 2,200 shares × $194.2791$427K
  • Lin Yu-HsinChief Executive Officer · Sep 4, 2026Open-market sale65,568 shares · $12.3M
    Avg. price $188.2112
    Show 10 price lots
    • 11,080 shares × $191.147$2.1M
    • 8,955 shares × $189.3414$1.7M
    • 8,111 shares × $193.1253$1.6M
    • 7,800 shares × $186.3235$1.5M
    • 6,200 shares × $187.2523$1.2M
    • 6,252 shares × $184.5244$1.2M
    • 4,955 shares × $183.2953$908K
    • 4,593 shares × $185.3443$851K
    • 4,209 shares × $192.5426$810K
    • 3,413 shares × $182.499$623K
  • Chuang Hao-YuanChief Financial Officer · Sep 4, 2026Open-market sale40,100 shares · $7.6M
    Avg. price $188.3451
    Show 9 price lots
    • 6,200 shares × $191.0893$1.2M
    • 6,200 shares × $189.2244$1.2M
    • 4,602 shares × $193.1176$889K
    • 4,600 shares × $186.345$857K
    • 3,900 shares × $187.1645$730K
    • 3,872 shares × $185.2809$717K
    • 3,759 shares × $183.2666$689K
    • 3,569 shares × $184.5737$659K
    • 3,398 shares × $192.4038$654K

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Belite Bio (BLTE) stock information

NASDAQ

Belite Bio (BLTE) is listed on NASDAQ. Its market capitalization is about $6.4B. On trailing-twelve-month earnings the P/E ratio is -82.38, and the P/B ratio is 8.35. Return on equity is -10.1%. These figures are computed in-house from official filings and are reference information only.

Belite Bio — frequently asked questions

What is the P/E ratio of Belite Bio (BLTE)?
On a trailing-twelve-month basis, BLTE trades at a P/E ratio of -82.38. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Belite Bio?
BLTE has a market capitalization of about $6.4B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.